Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Illumina, Inc., a San Diego, California-headquartered biotechnology firm, announced that its chief financial officer, Joydeep Goswani, is leaving. His departure was confirmed on Tuesday, April 9.
New Executives at the HQ
The company said it has appointed Ankur Dhingra as its new CFO. Goswani's successor is revealed to be an executive at Summit Therapeutics. He will be leaving the company, where he most recently served in the same chief financial role, to join Illumina.
Aside from Dhingra, Illumina is also welcoming Jakob Wedel, who has been named the new chief strategy and corporate development officer. At any rate, Reuters reported that the new CFO worked at CareDx, a medical test manufacturer, before being hired at Summit Therapeutics. He also spent almost 18 years at Agilent Technologies and has decades of experience in the life science business sector.
Relocation and Date of Leadership Appointments
Meanwhile, Illumina's newly appointed senior executives, Dhingra and Wedel, are set to be transferred to San Diego for their respective roles. The two will start working at the company on April 15. On the other hand, Goswami will remain in the company until June 30 and officially leave on July 1.
"I am proud of the talent joining our management team as we work to deliver on Illumina's mission to improve human health by unlocking the power of the genome," Illumina's chief executive officer, Jacob Thaysen, said in a press release. "Ankur brings deep financial expertise, investor and leadership experience, and industry knowledge to Illumina's CFO role, and Jakob has keen insights gained from 25 years in strategy leadership roles with global consulting firms."
The CEO added, "We are grateful to Joydeep for his many contributions to Illumina over more than four years, and for most recently leading these two key functions. Joydeep will continue with us for several weeks to support a smooth leadership transition."
Photo by: Illumina Press Release
